Hinge Health

Two founders who spent a year each rehabbing broken bones and a torn ACL walked away with the same conclusion: physical therapy is broken, and most people never finish it. Hinge Health is their answer, a virtual clinic for muscle and joint pain that pairs licensed clinicians with 3D motion tracking and an FDA-cleared nerve-stimulation wearable.

Daniel Perez and Gabriel Mecklenburg started the company in 2014 and rang the NYSE bell in May 2025 under the ticker HNGE. Revenue hit $587.9M in 2025, up roughly 50 percent, and the company guided 2026 to north of $818M. It is one of the few digital-health names to reach the public market and actually post operating income.

Hinge Health treats musculoskeletal conditions, the back, knee, shoulder, and pelvic pain that affects more than 1.7 billion people worldwide, without making anyone drive to a clinic three times a week. Members get a personalized exercise-therapy program plus a care team of a physical therapist, health coach, orthopedic specialist, and an AI care assistant.

The hook is TrueMotion, computer vision that turns an ordinary phone camera into a motion lab and gives real-time feedback while a member does their exercises. The stated goals are blunt: move beyond pain, avoid unnecessary surgery, and cut opioid use.

Musculoskeletal care is one of the biggest line items in any employer's health spend, and traditional PT loses people fast because it is inconvenient, expensive, and easy to quit. The default path too often runs toward imaging, injections, and surgery that a good exercise program could have avoided.

Hinge Health's pitch is that a digital-first program members can do at home keeps them engaged, catches the ones headed for a costly procedure earlier, and gives employers a claims-based return they can actually measure.

The buyer is B2B: self-insured employers, health plans, and pharmacy benefit managers who carry the cost of their members' MSK claims. The company says it is available to more than 20 million people across 2,550-plus employers, and reports client agreements with a large share of the Fortune 100.

The end user is the member in pain, but nobody swipes a credit card. Coverage flows through the employer or health plan, so the person doing knee exercises on their phone usually pays nothing out of pocket.

The core product is virtual exercise therapy with a human care team, but the parts that are hard to copy are the technology pieces around it. TrueMotion reads movement through a phone camera, and Enso is an FDA-cleared wearable that uses patented electrical waveforms for drug-free pain relief, exclusive to Hinge Health.

HingeSelect is the newer, more ambitious layer: an integrated care pathway that runs from digital PT to specialist visits, imaging, non-surgical procedures, and surgery itself, at rates the company says land 30 to 50 percent below commercial.

Hinge Health makes money through B2B contracts with employers, health plans, and PBMs, not by charging the patient. It leans on value-based pricing tied to outcomes and points to an independently validated 3.0x hard-dollar ROI as the reason a benefits leader signs.

Distribution is the quiet advantage. The company says it contracts through all five national health plans and three of three PBMs, with about 90 percent of implementation handled by partners, which makes it sticky and hard to rip out once it is embedded in a plan.

The name that comes up in every comparison is Sword Health, the other well-funded digital MSK player, and the two spend real energy publishing head-to-head ROI arguments against each other. Around them sit a longer tail of digital PT and chronic-pain apps.

Hinge Health's edge is less any single feature than the whole stack: the Enso wearable it owns outright, computer-vision motion tracking, and deep contractual wiring into national health plans and PBMs that raises the cost of switching.

The headline claim is a 3.0x hard-dollar ROI, validated against a commercial claims database rather than asserted in a brochure. On top of that sit the distribution proof points: contracts through all five national health plans, availability to more than 20 million people, and 2,550-plus employer clients.

HingeSelect's in-person network rates run 30 to 50 percent below commercial, per the company's own analysis of negotiated provider rates plus a 20 percent admin fee. Treat the savings figures as the company's framing, but the reach and the public financials are independently verifiable.

Members and customers tend to like the product, and the recurring employee praise is consistent: genuinely strong benefits, a mission people believe in, and smart, low-ego colleagues. Glassdoor sits around 3.7 out of 5.

The criticism clusters too, and it is worth taking seriously. Reviewers point to ego-driven management and uneven leadership decisions, thin room for career growth, and recent friction from aggressive return-to-office rules, layoffs, and offshoring. The 3-days-a-week office requirement shows up in the complaints and in the job postings alike.

Before going public, Hinge Health raised about $1.46B from crossover and growth investors including Tiger Global, Coatue, Alkeon Capital, and Whale Rock. The private valuation ran hot during the 2021 boom.

The real inflection was the May 2025 IPO, which priced at $32 a share and raised roughly $437M, with the stock jumping on its first day to imply a market cap near $3B. It was the digital-health listing that reopened a window most people assumed was shut.

Hinge Health cleared the bar most digital-health companies never reach: a public listing plus real operating income and 40-plus percent growth. The near-term question is durability, whether it can keep compounding as the easy MSK land-grab matures.

The expansion into migraine and surgery is the bet that the platform is bigger than one condition. Against Sword and a skeptical market that remembers the last digital-health hype cycle, the numbers have to keep doing the talking.

Engineering here has gone visibly AI-first. Job posts expect hands-on use of tools like Cursor and Claude Code to speed up development, and the R&D team openly talks about a workflow where agents draft code and humans review the reasoning.

The leadership principles read as a founder's operating manual: learn-it-all, hustle, accountability, lead at all levels, effective communication. The catch is the location math. Most roles are hybrid at three days a week in San Francisco, Montreal, or Bangalore, and the return-to-office push is one of the sharper points in employee reviews.

Pay is disclosed across a healthy chunk of roles and skews competitive for the space, with US engineering bands running from roughly $126K to $377K depending on level. Product, design, marketing, and operations bands are narrower but still land in six figures.

Most US roles add equity through an employee stock purchase plan with payroll deductions, plus a traditional or Roth 401(k) with a 2 percent match. Canada gets a Group RRSP with a 2 percent match instead. The numbers below are base salary only; the stock and match are the rest of the package.

The corporate entity is Hinge Health, Inc., registered at 455 Market Street, Suite 700, San Francisco. Clinical care runs through a separate structure, Hinge Health MSO, Inc., which manages a national network of licensed providers, so the tech company itself does not practice medicine.

Protected health information falls under HIPAA and a separate Notice of Privacy Practices rather than the general privacy policy. The company honors Global Privacy Control opt-out signals and lets members opt out of data sales and targeted advertising, though it does disclose some data to advertising partners by default.

The news flow since the IPO reads like a company pressing its advantage: record Q1 2026 results, a raised full-year outlook, its first Investor Day, and a steady march into new conditions beyond back-and-joint pain.

The expansion is the story to watch. Hinge Health added surgery to HingeSelect to close the loop on the MSK journey and launched a migraine care program built around the Enso wearable, a test of whether the model travels beyond musculoskeletal care.